BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 30066207)

  • 1. Palliative radiotherapy and chemoradiotherapy in stage IVA/B esophageal cancer patients with dysphagia.
    Kawamoto T; Nihei K; Sasai K; Karasawa K
    Int J Clin Oncol; 2018 Dec; 23(6):1076-1083. PubMed ID: 30066207
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of concurrent chemoradiotherapy as a palliative treatment in stage IVB esophageal cancer patients with dysphagia.
    Ikeda E; Kojima T; Kaneko K; Minashi K; Onozawa M; Nihei K; Fuse N; Yano T; Yoshino T; Tahara M; Doi T; Ohtsu A
    Jpn J Clin Oncol; 2011 Aug; 41(8):964-72. PubMed ID: 21742654
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II feasibility study of preoperative concurrent chemoradiotherapy with cisplatin plus 5-fluorouracil and elective lymph node irradiation for clinical stage II/III esophageal squamous cell carcinoma.
    Hashimoto J; Kato K; Ito Y; Kojima T; Akimoto T; Daiko H; Hamamoto Y; Matsushita H; Katano S; Hara H; Tanaka Y; Saito Y; Nagashima K; Igaki H
    Int J Clin Oncol; 2019 Jan; 24(1):60-67. PubMed ID: 30109544
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Concurrent chemoradiotherapy or endoscopic stenting for advanced squamous cell carcinoma of esophagus: a case-control study.
    Wong SK; Chiu PW; Leung SF; Cheung KY; Chan AC; Au-Yeung AC; Griffith JF; Chung SS; Ng EK
    Ann Surg Oncol; 2008 Feb; 15(2):576-82. PubMed ID: 18057993
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Palliative chemoradiotherapy versus radiotherapy alone for dysphagia in advanced oesophageal cancer: a multicentre randomised controlled trial (TROG 03.01).
    Penniment MG; De Ieso PB; Harvey JA; Stephens S; Au HJ; O'Callaghan CJ; Kneebone A; Ngan SY; Ward IG; Roy R; Smith JG; Nijjar T; Biagi JJ; Mulroy LA; Wong R;
    Lancet Gastroenterol Hepatol; 2018 Feb; 3(2):114-124. PubMed ID: 29248399
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TENERGY: multicenter phase II study of Atezolizumab monotherapy following definitive Chemoradiotherapy with 5-FU plus Cisplatin in patients with unresectable locally advanced esophageal squamous cell carcinoma.
    Bando H; Kotani D; Tsushima T; Hara H; Kadowaki S; Kato K; Chin K; Yamaguchi K; Kageyama SI; Hojo H; Nakamura M; Tachibana H; Wakabayashi M; Fukutani M; Togashi Y; Fuse N; Nishikawa H; Kojima T
    BMC Cancer; 2020 Apr; 20(1):336. PubMed ID: 32312286
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized phase 3 trial comparing paclitaxel plus 5-fluorouracil versus cisplatin plus 5-fluorouracil in Chemoradiotherapy for locally advanced esophageal carcinoma-the ESO-shanghai 1 trial protocol.
    Chen Y; Zhu Z; Zhao W; Li L; Ye J; Wu C; Tang H; Lin Q; Li J; Xia Y; Li Y; Zhou J; Zhao K
    Radiat Oncol; 2018 Feb; 13(1):33. PubMed ID: 29482649
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II study of chemoradiotherapy with 5-fluorouracil and cisplatin for Stage II-III esophageal squamous cell carcinoma: JCOG trial (JCOG 9906).
    Kato K; Muro K; Minashi K; Ohtsu A; Ishikura S; Boku N; Takiuchi H; Komatsu Y; Miyata Y; Fukuda H;
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(3):684-90. PubMed ID: 20932658
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Phase II clinical trial of concurrent chemoradiotherapy (cisplatin plus 5-fluorouracil) for esophageal cancer].
    Lin Q; Gao XS; Qiao XY; Chen K; Wang YD; Zhou ZG
    Ai Zheng; 2008 Oct; 27(10):1077-81. PubMed ID: 18851788
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is There a Correlation Between Clinical Complete Response and Pathological Complete Response After Neoadjuvant Chemoradiotherapy for Esophageal Squamous Cell Cancer?
    Liu SL; Xi M; Yang H; Yang YD; Wu YJ; Zhao L; Zhang P; Luo LL; Liu MZ
    Ann Surg Oncol; 2016 Jan; 23(1):273-81. PubMed ID: 26215200
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of postoperative chemoradiotherapy and chemoradiotherapy alone for esophageal cancer in North-West Iran.
    Mirinezhad SK; Somi MH; Shirmohamadi M; Seyednejad F; Jangjoo AG; Ghojazadeh M; Mohammadzadeh M; Naseri AR; Nasiri B
    Asian Pac J Cancer Prev; 2013; 14(6):3921-4. PubMed ID: 23886207
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Toxicity and Outcomes in Patients With and Without Esophageal Stents in Locally Advanced Esophageal Cancer.
    Francis SR; Orton A; Thorpe C; Stoddard G; Lloyd S; Anker CJ
    Int J Radiat Oncol Biol Phys; 2017 Nov; 99(4):884-894. PubMed ID: 28864404
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multicenter Phase 2 Study of Cisplatin and 5-Fluorouracil With Concurrent Radiation Therapy as an Organ Preservation Approach in Patients With Squamous Cell Carcinoma of the Cervical Esophagus.
    Zenda S; Kojima T; Kato K; Izumi S; Ozawa T; Kiyota N; Katada C; Tsushima T; Ito Y; Akimoto T; Hasegawa Y; Kanamaru M; Daiko H
    Int J Radiat Oncol Biol Phys; 2016 Dec; 96(5):976-984. PubMed ID: 27745985
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nonsurgical management of esophageal adenocarcinoma.
    Gujral DM; Hawkins MA; Leonulli BG; Ashley S; Chau I; Cunningham D; Tait D
    Clin Colorectal Cancer; 2011 Sep; 10(3):165-70. PubMed ID: 21855037
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II study of concurrent chemoradiotherapy at the dose of 50.4 Gy with elective nodal irradiation for Stage II-III esophageal carcinoma.
    Kato K; Nakajima TE; Ito Y; Katada C; Ishiyama H; Tokunaga SY; Tanaka M; Hironaka S; Hashimoto T; Ura T; Kodaira T; Yoshimura K
    Jpn J Clin Oncol; 2013 Jun; 43(6):608-15. PubMed ID: 23585687
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A retrospective comparison of neoadjuvant chemoradiotherapy regimens for locally advanced esophageal cancer.
    Sanford NN; Catalano PJ; Enzinger PC; King BL; Bueno R; Martin NE; Hong TS; Wo JY; Mamon HJ
    Dis Esophagus; 2017 Jul; 30(7):1-8. PubMed ID: 28475728
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Scoring system for predicting recurrence after chemoradiotherapy including 5-fluorouracil and platinum for patients with esophageal cancer.
    Kogo M; Suzuki A; Sunaga T; Kaneko K; Imawari M; Kiuchi Y
    Hepatogastroenterology; 2013; 60(128):1979-84. PubMed ID: 24088316
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Concurrent Selective Lymph Node Radiotherapy and S-1 Plus Cisplatin for Esophageal Squamous Cell Carcinoma: A Phase II Study.
    Wang X; Liu X; Li D; Wang X; Huang W; Li B
    Ann Surg Oncol; 2019 Jun; 26(6):1886-1892. PubMed ID: 30805810
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Utility of initial induction chemotherapy with 5-fluorouracil, cisplatin, and docetaxel (DCF) for T4 esophageal cancer: a propensity score-matched analysis.
    Makino T; Yamasaki M; Miyazaki Y; Wada N; Takahashi T; Kurokawa Y; Nakajima K; Takiguchi S; Mori M; Doki Y
    Dis Esophagus; 2018 Apr; 31(4):. PubMed ID: 29190316
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic factors in clinical T1N0M0 thoracic esophageal squamous cell carcinoma invading the muscularis mucosa or submucosa.
    Uchinami Y; Myojin M; Takahashi H; Harada K; Shimizu S; Hosokawa M
    Radiat Oncol; 2016 Jun; 11():84. PubMed ID: 27328734
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.